

Rhodium(III)-Catalyzed C7-Position C-H Alkenylation and Alkynylation of Indolines

Xiao-Fei Yang, Xu-Hong Hu, Chao Feng, and Teck-Peng Loh

Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences,

Nanyang Technological University, Singapore 637371

teckpeng@ntu.edu.sg

Supporting Information

Table of Contents	Page No.
General Information	S-2
Experimental Section	S-3
Substrate synthesis	S-3
Rh(III) catalyzed C-H alkenylation of indoline	S-3
Rh(III) catalyzed C-H alkynylation of indoline	S-4
H/D exchange experiment	S-4
Preparation of rhodacycle complex 1	S-5
Optimization of reaction condition	S-6
¹ H and ¹³ C NMR Spectra of Products	S-8
X-ray Data	S-79

General information

[RhCp*Cl₂]₂, Cu(OAc)₂, Cu(OTf)₂ and solvents were purchased from commercial suppliers and used as received unless otherwise noted. All reactions were carried out using 8mL sample vial or standard Schlenk technic. Reactions were monitored through thin layer chromatography [Merck 60 F254 precoated silica gel plate (0.2 mm thickness)]. Subsequent to elution, spots were visualized using UV radiation (254 nm) on Spectroline Model ENF-24061/F 254 nm. Further visualization was possible using basic solution of potassium permanganate. Flash chromatography was performed using Merck silica gel 60 with distilled solvents. HRMS spectra were recorded on a Waters Q-Tof Premier Spectrometer. ¹H NMR and ¹³C NMR spectra were recorded using Bruker Avance 400 MHz spectrometers. Chemical shifts for ¹H NMR and ¹³C NMR spectra were recorded using Bruker Avance 400 MHz spectrometers. Chemical shifts for ¹H NMR spectra are reported as δ in units of parts per million (ppm) downfield from SiMe₄ (δ 0.0) and relative to the signal of SiMe₄ (δ 0.00, singlet). Multiplicities were given as: s (singlet); brs (broad singlet); d (doublet); t (triplet); q (quartet); dd (doublets of doublet);ddd (doublets of doublets of doublet); td (triplet of doublet); m (multiplets); dd (doublet of doublet of triplet) and etc. Coupling constants are reported as a *J* value in Hz. Carbon nuclear magnetic resonance spectra (¹³C NMR) are reported as δ in units of parts per million (ppm) downfield from SiMe₄ (δ 0.0) and relative to the signal of chloroform-d (δ 77.00, triplet).

Experimental section


Substrate synthesis

1 were synthesized using reported method.^[1]

Alkynylodonium reagent was synthesized following the reported method.^[2]


Rh(III) catalyzed C-H alkenylation of indoline

General reaction procedure A



Synthetic procedure: The indoline **1** (0.14 mmol, 1 equiv.), styrene (0.70 mmol, 5.0 equiv.), $[\text{RhCp}^*\text{Cl}_2]_2$ (0.006 mmol, 4.5 mol%), $\text{Cu}(\text{OAc})_2$ (0.28 mmol, 2.0 equiv.) and DCE (1.0 mL) were placed in a 4 mL glass vial under N_2 . After stirring at 100 °C for 12 hours. Removal of the solvent in vacuo and purified by column chromatography afforded the desired product **3**.


General reaction procedure B



Synthetic procedure: The indoline **1** (0.14 mmol, 1 equiv.), 6-chlorohex-1-ene (0.70 mmol, 5.0 equiv.), $[\text{RhCp}^*\text{Cl}_2]_2$ (0.014 mmol, 10 mol%), $\text{Cu}(\text{OAc})_2$ (0.28 mmol, 2.0 equiv.) and DCE (1.0 mL) were placed in a 4 mL glass vial under N_2 . After stirring at 100 °C for 24 hours. Removal of the solvent in vacuo and purified by column chromatography afforded the desired product **3m**.

Rh(III) catalyzed C-H alkynylation of indoline


General reaction procedure C



Synthetic procedure: The indoline **1** (0.14 mmol, 1 equiv.), alkynylodonium reagent (0.18 mmol, 1.1 equiv.), $[\text{RhCp}^*\text{Cl}_2]_2$ (0.0056 mmol, 4 mol%), $\text{Cu}(\text{OTf})_2$ (0.016 mmol, 12 mol%) and DCE (1.0 mL) were placed in a 4 mL glass vial under N_2 . After stirring at 50 °C for 12 hours, saturated NaHCO_3


solution (2 mL) was added and the resulting mixture was extracted with dichloromethane (2x5 mL). Removal of the solvent in vacuo and purified by column chromatography afforded the desired product **6a**.

General reaction procedure D




Synthetic procedure: The indoline **1** (0.14 mmol, 1 equiv.), alkynyliodonium reagent (0.36 mmol, 2.5 equiv.), $[\text{RhCp}^*\text{Cl}_2]_2$ (0.0056 mmol, 4 mol%), $\text{Cu}(\text{OTf})_2$ (0.028 mmol, 20 mol%) and DCE (1.0 mL) were placed in a 4 mL glass vial under N_2 . After stirring at 50 °C for 12 hours, saturated NaHCO_3 solution (2 mL) was added and the resulting mixture was extracted with dichloromethane (2x5 mL). Removal of the solvent in vacuo and purified by column chromatography afforded the desired product **6**.

General reaction procedure E



Synthetic procedure: The indoline **1** (0.14 mmol, 1 equiv.), alkynyliodonium reagent (0.36 mmol, 2.5 equiv.), $[\text{RhCp}^*\text{Cl}_2]_2$ (0.0056 mmol, 4 mol%), $\text{Cu}(\text{OTf})_2$ (0.028 mmol, 20 mol%) and DCE (1.0 mL) were placed in a 4 mL glass vial under N_2 . After stirring at room temperature for 3 hours, saturated NaHCO_3 solution (2 mL) was added and the resulting mixture was extracted with dichloromethane (2x5 mL). Removal of the solvent in vacuo and purified by column chromatography afforded the desired product **6n**.

H/D exchange experiment




Synthetic procedure: The indoline **1** (0.14 mmol, 1 equiv.), $[\text{RhCp}^*\text{Cl}_2]_2$ (0.006 mmol, 4.5 mol%), $\text{Cu}(\text{OAc})_2$ (0.28 mmol, 2.0 equiv.) and DCE/ CD_3OD 1 mL (v:v = 6:1) were placed in a 4 mL glass vial under N_2 . After stirring at 100 °C for 12 hours. Removal of the solvent in vacuo and purified by column chromatography.

Preparation of rhodacycle complex 1

Preparation of a rhodacycle complex 1 was carried out according to the reported Jones' procedure: A solution of indoline **1** (0.14 mmol), $[\text{RhCp}^*\text{Cl}_2]_2$ (0.063 mmol) and NaOAc (0.39 mmol) in CH_2Cl_2 (3 mL) was stirred at room temperature under N_2 atmosphere for 24 h. The crude mixture was filtered through a pad of celite washing with CH_2Cl_2 (5 mL x 2) and concentrated under reduced pressure. After recrystallization from $\text{CH}_2\text{Cl}_2/\text{hexane}$, rhodacycle complex 1 was obtained as a red crystal (41.3 mg, 63%).


Optimaization of reaction condition

Table S1



Entry	Cat.	Oxidant	Solvent	Yield ^b (%)
1	[RhCp*Cl ₂] ₂	AgOAc	DCE	48
2	[RhCp*Cl ₂] ₂	BQ	DCE	N.R.
3	[RhCp*Cl ₂] ₂	Ag ₂ CO ₃	DCE	N.R.
4	[RhCp*Cl ₂] ₂	Ag ₂ O	DCE	trace
5	[RhCp*Cl ₂] ₂	Cu(OAc) ₂	DCE	83
6	[RhCp*Cl ₂] ₂	Cu(OAc) ₂	Toluene	47
7	[RhCp*Cl ₂] ₂	Cu(OAc) ₂	THF	58
8	[Ru(<i>p</i> -cymene)Cl ₂] ₂	Cu(OAc) ₂	DCE	N.R.
9	Pd(OAc) ₂	BQ	DCE	N.R.
10	-	Cu(OAc) ₂	DCE	N.R.

^aThe reactions were carried out at 100 °C using **1a** (0.14 mmol), **2a** (0.7 mmol), oxidant (0.28 mmol), catalyst (0.006 mmol) in solvent (1 mL) for 12 h. ^bIsolated yields.


Table S2

entry	cat.	additives	Temp (°C)	yield ^b (%)
1	[RhCp*Cl ₂] ₂	Cu(OAc) ₂	50	24
2	[RhCp*Cl ₂] ₂	Cu(OTf) ₂	50	77
3	[RhCp*Cl ₂] ₂	Cu(OTf) ₂	r.t.	33
4	[RhCp*Cl ₂] ₂	Zn(OTf) ₂	50	74
5	[RhCp*Cl ₂] ₂	AgSbF ₆	50	46
6	[RhCp*Cl ₂] ₂	AgNTf ₂	50	52
7	[RhCp*Cl ₂] ₂	-	50	N.R.
8	-	Cu(OTf) ₂	50	N.R.
9	[RhCp*(CH ₃ CN) ₃] (SbF ₆) ₂	Cu(OTf) ₂	50	71
10	[Ru(<i>p</i> -cymene)Cl ₂] ₂	Cu(OTf) ₂	50	N.R.
11	Pd(OAc) ₂	Cu(OTf) ₂	50	-

[a] Unless otherwise noted, the reactions were carried out at 50 °C using 1 (0.14 mmol), alkyne (0.18 mmol), additives (0.16 mmol), catalyst (0.0056 mmol) in solvent (1 mL) for 12 h. [b] Isolated yields.


¹H and ¹³C NMR Spectra of Products

(E)-1-(pyridin-2-yl)-7-styrylindoline (3a)




Following the general reaction procedure A, **3a** was obtained as a yellow solid (34.6 mg, 0.116 mmol, Yield: 83%); m.p. = 134–136 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.31 – 8.29 (m, 1H), 7.47 (d, *J* = 7.9 Hz, 1H), 7.41 – 7.31 (m, 1H), 7.28 – 7.14 (m, 6H), 7.02 (d, *J* = 7.9 Hz, 1H), 6.97 (d, *J* = 16.4 Hz, 1H), 6.83 – 6.70 (m, 3H), 4.40 (t, *J* = 7.9 Hz, 2H), 3.08 (t, *J* = 7.9 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 157.99, 147.93, 143.17, 137.63, 136.80 × 2, 135.39, 128.55 × 2, 127.83, 127.38, 126.38 × 2, 125.04, 125.67, 123.99, 123.09, 115.66, 111.15, 54.23, 29.38; HRMS (ESI): m/z calculated for [C₂₁H₁₉N₂]⁺ [M + H]⁺: 299.1548, Found: 299.1545; FTIR (NaCl): ν 3442, 2916, 1583, 1463, 1429, 1327, 972, 732, 690 cm⁻¹

(E)-7-(4-methylstyryl)-1-(pyridin-2-yl)indoline (3b)



Following the general reaction procedure A, **3b** was obtained as a yellow solid (27.5 mg, 0.088 mmol, Yield: 63%); m.p. = 127–129 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.31 – 8.29 (m, 1H), 7.46 (d, *J* = 7.9 Hz, 1H), 7.38 – 7.33 (m, 1H), 7.18 – 6.90 (m, 7H), 6.76 – 6.66 (m, 3H), 4.40 (t, *J* = 8.0 Hz, 2H), 3.07 (t, *J* = 8.0 Hz, 2H), 2.29 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 158.00, 147.92, 143.04, 137.22, 136.65, 135.34, 134.81, 129.23 × 2, 127.72, 126.26 × 2, 125.37, 125.21, 124.50, 123.72, 123.03, 115.52, 111.06, 54.13, 29.35, 21.16; HRMS (ESI): m/z calculated for [C₂₂H₂₁N₂]⁺ [M + H]⁺: 313.1705, Found: 313.1703; FTIR (NaCl): ν 3583, 2916, 1583, 1465, 1429, 1371, 970, 806, 771 cm⁻¹


(E)-7-(4-methoxystyryl)-1-(pyridin-2-yl)indoline (3c)



Following the general reaction procedure A, **3c** was obtained as a yellow solid (30.8 mg, 0.093 mmol, Yield: 67%); m.p. = 97–99 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.36 – 8.35 (m, 1H), 7.48 (d, *J* = 7.9 Hz, 1H), 7.43 – 7.35 (m, 1H), 7.21 – 7.14 (m, 3H), 7.03 (t, *J* = 7.6 Hz, 1H), 6.96 (d, *J* = 16.3 Hz, 1H), 6.84 – 6.71 (m, 4H), 6.65 (d, *J* = 16.3 Hz, 1H), 4.44 (t, *J* = 8.0 Hz, 2H), 3.80 (s, 3H), 3.10 (t, *J* = 8.9 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 159.12, 157.98, 147.88, 142.88, 136.64, 135.35, 130.40, 127.53, 127.39,


125.38, 124.35 × 2, 124.30, 123.54, 123.07, 115.49, 113.98 × 2, 111.11, 55.22, 54.14, 29.37; HRMS (ESI): m/z calculated for [C₂₂H₂₁N₂O]⁺ [M + H]⁺: 329.1654, Found: 329.1651; FTIR (NaCl): ν 3053, 2985, 2304, 1604, 1583, 1510, 1465, 1265, 1174, 1033, 894 cm⁻¹

(E)-7-(4-(tert-butyl)styryl)-1-(pyridin-2-yl)indoline (3d)




Following the general reaction procedure A, **3d** was obtained as a white solid (46.6 mg, 0.13 mmol, Yield: 94%); m.p. = 165–167 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.32 – 8.30 (m, 1H), 7.47 (d, J = 8.3 Hz, 1H), 7.36 (ddd, J = 8.3, 7.2, 2.0 Hz, 1H), 7.31 – 7.23 (m, 2H), 7.14 (d, J = 8.3 Hz, 3H), 7.07 – 6.92 (m, 2H), 6.78 – 6.69 (m, 3H), 4.40 (t, J = 7.9 Hz, 2H), 3.06 (t, J = 7.9 Hz, 2H), 1.28 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 158.03, 150.44, 147.93, 143.02, 136.71, 135.35, 134.78, 127.56, 126.07 × 2, 125.46, 125.43 × 2, 125.25, 124.44, 123.71, 123.04, 115.52, 110.96, 54.13, 34.51, 31.21 × 3, 29.33; HRMS (ESI): m/z calculated for [C₂₅H₂₇N₂]⁺ [M + H]⁺: 355.2174, Found: 355.2171; FTIR (NaCl): ν 2960, 2916, 1581, 1465, 1429, 1363, 1153, 819, 771 cm⁻¹

(E)-4-(2-(1-(pyridin-2-yl)indolin-7-yl)vinyl)phenyl acetate (3e)



Following the general reaction procedure A, **3e** was obtained as a yellow solid (46.4 mg, 0.13 mmol, Yield: 93%); m.p. = 96–98 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.30 – 8.28 (m, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.35 – 7.39 (m, 1H), 7.20 – 7.15 (m, 3H), 7.00 (t, J = 7.6 Hz, 1H), 6.98 – 6.92 (m, 3H), 6.79 – 6.73 (m, 2H), 6.70 (d, J = 5.7 Hz, 1H), 4.39 (t, J = 7.9 Hz, 2H), 3.07 (t, J = 7.9 Hz, 2H), 2.26 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 169.41, 157.93, 149.79, 147.92, 143.14, 136.75, 135.37, 135.33, 127.19 × 2, 126.64, 126.55, 124.79, 124.54, 123.98, 123.02, 121.58 × 2, 115.65, 110.98, 54.15, 29.28, 21.05; HRMS (ESI): m/z calculated for [C₂₃H₂₁N₂O₂]⁺ [M + H]⁺: 357.1603, Found: 357.1601; FTIR (NaCl): ν 3412, 3049, 1759, 1583, 1504, 1469, 1433, 1369, 1193, 1165, 1014 cm⁻¹


(E)-7-(4-bromostyryl)-1-(pyridin-2-yl)indoline (3f)



Following the general reaction procedure A, **3f** was obtained as a yellow solid (43.2 mg, 0.115 mmol,


Yield: 82%); m.p. = 117-119 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.29 – 8.27 (m, 1H), 7.43 (d, *J* = 7.6 Hz, 1H), 7.39 – 7.31 (m, 3H), 7.17 (dd, *J* = 7.6, 0.8 Hz, 1H), 7.04 (d, *J* = 8.5 Hz, 2H), 7.00 (t, *J* = 7.6 Hz, 1H), 6.87 (d, *J* = 16.4 Hz, 1H), 6.75 – 6.70 (m, 3H), 4.38 (t, *J* = 8.0 Hz, 2H), 3.08 (t, *J* = 8.0 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 157.89, 147.96, 143.21, 136.67, 136.53, 135.32, 131.58 × 2, 127.72 × 2, 127.14, 126.31, 124.59, 124.51, 124.17, 123.00, 120.98, 115.68, 111.02, 54.14, 29.27; HRMS (ESI): m/z calculated for [C₂₁H₁₈BrN₂]⁺ [M + H]⁺: 377.0653, Found: 377.0650; FTIR (NaCl): ν 3421, 2848, 1635, 1585, 1463, 1429, 1261, 1151, 1070, 810 cm⁻¹

(E)-7-(4-chlorostyryl)-1-(pyridin-2-yl)indoline (3g)




Following the general reaction procedure A, **3g** was obtained as a yellow solid (36.3 mg, 0.11 mmol, Yield: 78%); m.p. = 94-96 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.30 – 8.28 (m, 1H), 7.43 (d, *J* = 7.7 Hz, 1H), 7.36 (ddd, *J* = 8.5, 7.7, 2.0 Hz, 1H), 7.20 – 7.16 (m, 3H), 7.14 – 7.07 (m, 2H), 7.00 (t, *J* = 7.6 Hz, 1H), 6.89 (d, *J* = 16.4 Hz, 1H), 6.80 – 6.65 (m, 3H), 4.38 (t, *J* = 8.0 Hz, 2H), 3.08 (t, *J* = 8.0 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 157.88, 147.92, 143.18, 136.72, 136.09, 135.33, 132.85, 128.66 × 2, 127.41 × 2, 127.01, 126.34, 124.60, 124.56, 124.15, 123.03, 115.69, 111.08, 54.18, 29.29; HRMS (ESI): m/z calculated for [C₂₁H₁₈ClN₂]⁺ [M + H]⁺: 333.1159, Found: 333.1153; FTIR (NaCl): ν 3047, 2916, 2846, 1581, 1444, 1371, 1261, 1091, 970, 864, 813 cm⁻¹

(E)-7-(3-nitrostyryl)-1-(pyridin-2-yl)indoline (3h)




Following the general reaction procedure A, **3h** was obtained as a yellow solid (41.1 mg, 0.12 mmol, Yield: 85%); m.p. = 133-135 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.28 – 8.30 (m, 1H), 8.13 – 7.89 (m, 2H), 7.50 – 7.33 (m, 4H), 7.21 (d, *J* = 7.2 Hz, 1H), 7.02 (t, *J* = 7.6 Hz, 1H), 6.96 (d, *J* = 16.4 Hz, 1H), 6.90 (d, *J* = 16.4 Hz, 1H), 6.82 – 6.72 (m, 2H), 4.38 (t, *J* = 8.0 Hz, 2H), 3.12 (t, *J* = 8.0 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 157.81, 148.60, 148.06, 143.57, 139.57, 136.85, 135.32, 131.71, 129.68, 129.34, 124.90, 124.88, 124.77, 123.70, 122.97, 121.66, 120.91, 116.05, 111.23, 54.24, 29.25; HRMS (ESI): m/z calculated for [C₂₁H₁₈N₃O₂]⁺ [M + H]⁺: 344.1399, Found: 344.1395; FTIR (NaCl): ν 2954, 2848, 1583, 1519, 1429, 1348, 1263, 960 cm⁻¹

(E)-7-(3-methylstyryl)-1-(pyridin-2-yl)indoline (3i)




Following the general reaction procedure A, **3i** was obtained as a yellow oil (36.7 mg, 0.12 mmol, Yield: 84%); ¹H NMR (400 MHz, CDCl₃) δ 8.56 – 8.20 (m, 1H), 7.46 (d, *J* = 7.8 Hz, 1H), 7.36 (ddd, *J* = 8.4, 7.8, 2.0 Hz, 1H), 7.20 – 7.06 (m, 2H), 7.06 – 6.89 (m, 5H), 6.75 – 6.71 (m, 3H), 4.40 (t, *J* = 8.0 Hz, 2H), 3.08 (t, *J* = 8.0 Hz, 2H), 2.26 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 157.93, 147.84, 143.07, 138.00, 137.51, 136.80, 135.32, 128.38, 128.15, 127.86, 127.15, 126.13, 125.03, 124.55, 123.85, 123.44, 123.04, 115.56, 111.16, 54.17, 29.33, 21.29; HRMS (ESI): m/z calculated for [C₂₂H₂₁N₂]⁺ [M + H]⁺: 313.1705, Found: 313.1703; FTIR (NaCl): ν 3047, 2916, 1693, 1583, 1427, 1263, 1153, 1056, 856 cm⁻¹

(E)-7-(2-methylstyryl)-1-(pyridin-2-yl)indoline (3j)




Following the general reaction procedure A, **3j** was obtained as yellow solid (33.7 mg, 0.11 mmol, Yield: 77%); m.p. = 104–106 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.33 – 8.28 (m, 1H), 7.45 (d, *J* = 7.9 Hz, 1H), 7.42 – 7.34 (m, 1H), 7.21 – 6.98 (m, 7H), 6.82 – 6.61 (m, 3H), 4.40 (t, *J* = 8.0 Hz, 2H), 3.07 (t, *J* = 8.0 Hz, 2H), 2.28 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 157.85, 147.89, 143.02, 136.73, 136.48, 135.60, 135.43, 130.16, 127.54, 127.23, 126.01, 125.96, 125.56, 125.21, 125.15, 123.87, 123.10, 115.62, 111.16, 54.22, 29.31, 19.72; HRMS (ESI): m/z calculated for [C₂₂H₂₁N₂]⁺ [M + H]⁺: 313.1705, Found: 313.1707; FTIR (NaCl): ν 3421, 1637, 1583, 1463, 1429, 1371, 1263, 1153, 1056, 985, 970 cm⁻¹

(E)-7-(2-chlorostyryl)-1-(pyridin-2-yl)indoline (3k)




Following the general reaction procedure A, **3k** was obtained as a yellow oil (43.2 mg, 0.13 mmol, Yield: 93%); ¹H NMR (400 MHz, CDCl₃) δ 8.29 (d, *J* = 3.5 Hz, 1H), 7.52 (d, *J* = 7.8 Hz, 1H), 7.45 – 7.28 (m, 3H), 7.20 – 7.14 (m, 2H), 7.12 – 7.01 (m, 3H), 6.82 – 6.65 (m, 3H), 4.39 (t, *J* = 8.0 Hz, 2H), 3.09 (t, *J* = 8.0 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 157.99, 147.89, 143.33, 136.86, 135.59, 135.29, 133.18, 129.58, 128.83, 128.21, 126.76, 126.30, 124.99, 124.79, 124.34, 123.72, 123.13, 115.71, 111.07, 54.23, 29.29; HRMS (ESI): m/z calculated for [C₂₁H₁₈ClN₂]⁺ [M + H]⁺: 333.1159, Found: 333.1151; FTIR (NaCl): ν 3053, 2956, 1583, 1469, 1429, 1261, 1153, 1051, 1033, 970 cm⁻¹

7-((1*E*, 3*E*)-4-phenylbuta-1,3-dien-1-yl)-1-(pyridin-2-yl)indoline (3l)




Following the general reaction procedure A, **3l** was obtained as a yellow solid (29.5 mg, 0.09 mmol, Yield: 65%); m.p. = 138–140 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.31–8.30 (m, 1H), 7.41 (d, *J* = 7.6 Hz, 2H), 7.35 (d, *J* = 7.6 Hz, 2H), 7.28 (t, *J* = 7.6 Hz, 2H), 7.20 – 7.13 (m, 2H), 6.99 (t, *J* = 7.6 Hz, 1H), 6.82 (dd, *J* = 15.4, 10.5 Hz, 1H), 6.78 – 6.68 (m, 3H), 6.57 (d, *J* = 15.4 Hz, 1H), 6.34 (d, *J* = 15.4 Hz, 1H), 4.39 (t, *J* = 7.9 Hz, 2H), 3.05 (t, *J* = 7.9 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 158.02, 147.88, 142.92, 137.29, 136.72, 135.49, 132.41, 130.15, 129.54, 128.73, 128.54 × 2, 127.41, 126.28 × 2, 125.32, 124.39, 123.88, 123.16, 115.65, 110.98, 54.25, 29.30; HRMS (ESI): m/z calculated for [C₂₃H₂₁N₂]⁺ [M + H]⁺: 325.1705, Found: 325.1706; FTIR (NaCl): ν 3442, 2916, 1587, 1463, 1429, 1361, 1263, 987 cm⁻¹

(E)-7-(6-chlorohex-1-en-1-yl)-1-(pyridin-2-yl)indoline (3m)



Following the general reaction procedure B, **3m** was obtained as a colorless oil (22.7 mg, 0.07 mmol, Yield: 52%); ¹H NMR (400 MHz, CDCl₃) *E* form δ 8.36 – 8.20 (m, 1H), 7.42 (ddd, *J* = 8.5, 7.2, 2.0 Hz, 1H), 7.26 (m, 1H), 7.12 (dd, *J* = 7.2, 2.0 Hz, 1H), 6.97 (t, *J* = 7.2 Hz, 1H), 6.75 (dd, *J* = 7.2, 4.9 Hz, 1H), 6.64 (d, *J* = 8.5 Hz, 1H), 6.13 – 5.98 (m, 2H), 4.37 (t, *J* = 7.9 Hz, 2H), 3.46 (t, *J* = 6.7 Hz, 2H), 3.04 (t, *J* = 7.9 Hz, 2H), 2.07 (m, 2H), 1.71–1.65 (m, 2H), 1.50 – 1.37 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 158.01, 147.94, 142.43, 136.41, 135.37, 129.80, 128.15, 125.67, 124.83, 123.34, 123.10, 115.42, 111.33, 54.21, 44.88, 32.18, 31.92, 29.39, 26.39; HRMS (ESI): m/z calculated for [C₁₉H₂₂N₂]⁺ [M + H]⁺: 313.1472, Found: 313.1469; FTIR (NaCl): ν 2954, 2850, 1585, 1469, 1431, 1056, 975, 771, 740 cm⁻¹


3n



Following the general reaction procedure B, **3n** was obtained as a colorless oil (15.9 mg, 0.05 mmol, Yield: 34%); ¹H NMR (*E* and major positional isomer, 400 MHz, CDCl₃) δ 8.31 – 8.25 (m, 1H), 7.53 –


7.37 (m, 1H), 7.31 – 7.08 (m, 2H), 6.96 (td, J = 7.5, 2.7 Hz, 1H), 6.75 (m, 1H), 6.64 (m, 1H), 6.09 – 6.01 (m, 1H), 5.47 – 5.31 (m, 1H), 4.41 – 4.32 (m, 2H), 3.22 – 2.96 (m, 2H), 2.11 – 1.84 (m, 2H), 1.34 – 1.18 (m, 12H), 0.87 (t, J = 6.9 Hz, 3H). ^{13}C NMR (*E* and major positional isomer, 101 MHz, CDCl_3) δ 158.46, 157.90, 147.99, 147.75, 143.58, 142.28, 136.86, 136.38, 135.32, 134.63, 132.58, 131.11, 129.08, 128.23, 127.46, 127.39, 126.01, 124.79, 123.17, 123.12, 123.10, 122.50, 115.43, 115.28, 111.44, 111.34, 54.90, 54.17, 36.01, 33.08, 32.53, 31.88, 31.86, 29.90, 29.47, 29.40, 29.24, 29.23, 29.224, 29.16, 29.15, 29.12, 27.18, 22.66, 22.65, 14.09; HRMS (ESI): m/z calculated for $[\text{C}_{23}\text{H}_{31}\text{N}_2]^+$ $[\text{M} + \text{H}]^+$: 335.2487, Found: 335.2489; FTIR (NaCl): ν 2924, 2854, 1585, 1469, 1431, 1369, 1153, 1056, 972, 771 cm^{-1}

(*E*)-7-(3-phenylprop-1-en-1-yl)-1-(pyridin-2-yl)indoline (3o)




Following the general reaction procedure B, **3o** was obtained as a colorless oil (21.9 mg, 0.07 mmol, Yield: 50%); ^1H NMR (400 MHz, CDCl_3) major δ 8.31–8.29 (m, 1H), 7.53 – 7.49 (m, 1H), 7.34 – 7.10 (m, 7H), 6.97 (t, J = 7.5 Hz, 1H), 6.82 – 6.76 (m, 1H), 6.68 (d, J = 8.2 Hz, 1H), 6.30 (d, J = 15.9 Hz, 1H), 6.24 (dt, J = 15.9, 6.2 Hz, 1H), 4.27 (t, J = 7.9 Hz, 2H), 3.32 (d, J = 6.2 Hz, 2H), 3.08 (t, J = 7.9 Hz, 2H); ^{13}C NMR (101 MHz, CDCl_3) δ 158.48, 148.06, 143.81, 137.69, 137.03, 134.72, 131.38, 128.65, 128.51, 128.45 \times 2, 128.37, 126.94, 126.07 \times 2, 123.27, 122.83, 115.66, 111.57, 54.99, 36.57, 29.94; HRMS (ESI): m/z calculated for $[\text{C}_{22}\text{H}_{21}\text{N}_2]^+$ $[\text{M} + \text{H}]^+$: 313.1705, Found: 313.1701; FTIR (NaCl): ν 2920, 1643, 1465, 1431, 1369, 1153, 1056, 968, 698 cm^{-1}

(*E*)-2-methyl-1-(pyridin-2-yl)-7-styrylindoline (3p)




Following the general reaction procedure A, **3p** was obtained as a yellow oil (40.6 mg, 0.13 mmol, Yield: 95%); ^1H NMR (400 MHz, CDCl_3) δ 8.34 – 8.23 (m, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.34 (ddd, J = 8.5, 7.8, 2.0 Hz, 1H), 7.26 – 7.10 (m, 6H), 7.08 – 6.87 (m, 2H), 6.78 – 6.68 (m, 3H), 4.88 – 4.63 (m, 1H), 3.43 (dd, J = 15.5, 8.5 Hz, 1H), 2.51 (d, J = 15.5 Hz, 1H), 1.47 (d, J = 6.6 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 157.84, 148.03, 141.94, 137.62, 136.67, 134.11, 128.45 \times 2, 127.50, 127.26, 126.43, 126.33 \times 2, 125.45, 124.41, 124.39, 123.06, 115.68, 110.53, 61.63, 36.75, 22.45; HRMS (ESI): m/z calculated for $[\text{C}_{22}\text{H}_{21}\text{N}_2]^+$ $[\text{M} + \text{H}]^+$: 313.1705, Found: 313.1702; FTIR (NaCl): ν 3442, 3051, 2972, 2920, 1581, 1467, 1429, 1265, 1153, 1060, 983, 968, 910 cm^{-1}

(*E*)-7-(4-bromostyryl)-2-methyl-1-(pyridin-2-yl)indoline (3q)




Following the general reaction procedure A, **3q** was obtained as a yellow oil (49.2 mg, 0.13 mmol, Yield: 90%); ¹H NMR (400 MHz, CDCl₃) δ 8.28 – 8.25 (m, 1H), 7.51 – 7.41 (m, 1H), 7.39 – 7.31 (m, 3H), 7.17 (d, *J* = 7.4 Hz, 1H), 7.11 – 6.98 (m, 3H), 6.89 (d, *J* = 16.4 Hz, 1H), 6.82 – 6.59 (m, 3H), 4.83 – 4.70 (m, 1H), 3.45 (dd, *J* = 15.0, 8.5 Hz, 1H), 2.51 (d, *J* = 15.0 Hz, 1H), 1.47 (d, *J* = 6.6 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 157.81, 148.08, 142.06, 136.69, 136.61, 134.13, 131.57 × 2, 127.77 × 2, 127.25, 126.13, 125.04, 124.69, 124.44, 123.08, 120.95, 115.81, 110.56, 61.72, 36.77, 22.49; HRMS (ESI): m/z calculated for [C₂₂H₂₀BrN₂]⁺ [M + H]⁺: 391.0810, Found: 391.0806; FTIR (NaCl): ν 3074, 2970, 1581, 1444, 1365, 1334, 1303, 1072, 864, 692 cm⁻¹

(E)-2-phenyl-1-(pyridin-2-yl)-7-styrylindoline (**3r**)



Following the general reaction procedure A, **3r** was obtained as a yellow oil (39.3 mg, 0.11 mmol, Yield: 75%); ¹H NMR (400 MHz, CDCl₃) δ 8.25 – 8.23 (m, 1H), 7.53 (d, *J* = 7.7 Hz, 1H), 7.40 (t, *J* = 7.7 Hz, 3H), 7.31 (t, *J* = 7.7 Hz, 2H), 7.24 – 7.14 (m, 6H), 7.12 – 6.98 (m, 3H), 6.92 (d, *J* = 16.3 Hz, 1H), 6.77 – 6.73 (m, 2H), 5.67 (d, *J* = 8.8 Hz, 1H), 3.85 (dd, *J* = 15.5, 8.8 Hz, 1H), 2.93 (d, *J* = 15.5 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 157.83, 148.10, 144.35, 142.89, 137.69, 136.93, 133.14, 128.63 × 2, 128.51 × 2, 127.62, 127.33, 127.04, 126.58, 126.39 × 2, 125.58 × 2, 125.24, 124.61, 124.24, 123.52, 116.17, 110.74, 68.45, 38.83; HRMS (ESI): m/z calculated for [C₂₇H₂₃N₂]⁺ [M + H]⁺: 375.1861, Found: 375.1864; FTIR (NaCl): ν 3061, 3028, 2956, 2916, 2846, 2245, 1583, 1568, 1556, 1446, 1371, 1265, 1244, 1153, 1060, 968 cm⁻¹


(E)-3-methyl-1-(pyridin-2-yl)-7-styrylindoline (**3s**)



Following the general reaction procedure A, **3s** was obtained as a yellow oil (39.8 mg, 0.13 mmol, Yield: 91%); ¹H NMR (400 MHz, CDCl₃) δ 8.42 – 8.19 (m, 1H), 7.48 (d, *J* = 7.8 Hz, 1H), 7.41 – 7.32 (m, 1H), 7.28 – 7.10 (m, 6H), 7.04 (t, *J* = 7.8 Hz, 1H), 6.97 (d, *J* = 16.4 Hz, 1H), 6.79 – 6.71 (m, 3H), 4.55 (dd, *J* = 10.8, 8.2 Hz, 1H), 3.92 (dd, *J* = 10.8, 6.9 Hz, 1H), 3.49 – 3.31 (m, 1H), 1.28 (d, *J* = 6.9 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 158.17, 147.98, 142.78, 140.58, 137.59, 136.77, 128.49 × 2, 127.77, 127.32, 126.32 × 2, 126.29, 125.01, 124.68, 123.21, 122.75, 115.53, 110.78, 62.04, 36.06,


19.12; HRMS (ESI): m/z calculated for $[C_{22}H_{21}N_2]^+$ [M + H]⁺: 313.1705, Found: 313.1704; FTIR (NaCl): ν 3583, 3406, 2956, 2918, 1581, 1469, 1263, 1153, 1072, 910 cm⁻¹

(E)-4-methyl-1-(pyridin-2-yl)-7-styrylindoline (3t)




Following the general reaction procedure A, **3t** was obtained as a yellow oil (29.3 mg, 0.09 mmol, Yield: 67%); ¹H NMR (400 MHz, CDCl₃) δ 8.31 – 8.29 (m, 1H), 7.40 (d, *J* = 8.0 Hz, 1H), 7.37 – 7.31 (m, 1H), 7.26 – 7.10 (m, 5H), 6.93 (d, *J* = 16.4 Hz, 1H), 6.85 (d, *J* = 8.0 Hz, 1H), 6.80 – 6.65 (m, 3H), 4.41 (t, *J* = 8.0 Hz, 2H), 2.98 (t, *J* = 8.0 Hz, 2H), 2.27 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 158.11, 147.90, 142.79, 137.75, 136.67, 133.77, 133.64, 128.47 \times 2, 127.13, 126.90, 126.36, 126.22 \times 2, 124.61, 124.40, 122.46, 115.52, 111.12, 53.94, 28.06, 18.74; HRMS (ESI): m/z calculated for $[C_{22}H_{21}N_2]^+$ [M + H]⁺: 313.1705, Found: 313.1703; FTIR (NaCl): ν 3053, 2916, 2850, 2218, 1593, 1433, 1325, 1300, 1267, 1153, 1058, 968, 908, 692 cm⁻¹

(E)-7-(2-(bicyclo[4.2.0]octa-1(6),2,4-trien-3-yl)vinyl)-2-methyl-1-(pyridin-2-yl)indoline (3u)



Following the general reaction procedure A, **3u** was obtained as a yellow oil (39.8 mg, 0.12 mmol, Yield: 84%); ¹H NMR (400 MHz, CDCl₃) δ 8.30 – 8.28 (m, 1H), 7.47 (d, *J* = 7.8 Hz, 1H), 7.34 (ddd, *J* = 8.5, 7.8, 2.0 Hz, 1H), 7.14 (d, *J* = 7.8 Hz, 1H), 7.09 – 6.89 (m, 5H), 6.75 – 6.62 (m, 3H), 4.80 (qd, *J* = 8.5, 6.6 Hz, 1H), 3.43 (dd, *J* = 15.5, 8.5 Hz, 1H), 3.10 – 3.09 (m, 4H), 2.50 (d, *J* = 15.5 Hz, 1H), 1.46 (d, *J* = 6.6 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 157.84, 147.96, 145.99, 145.33, 141.77, 136.69, 136.52, 134.13, 128.79, 125.86, 125.06 \times 2, 124.31, 124.14, 123.12, 122.51, 119.91, 115.60, 110.56, 61.61, 36.77, 29.39, 29.21, 22.43; HRMS (ESI): m/z calculated for $[C_{24}H_{23}N_2]^+$ [M + H]⁺: 339.1861, Found: 339.1860; FTIR (NaCl): ν 3064, 2964, 2924, 2245, 1583, 1469, 1429, 1153 cm⁻¹


(E)-5-bromo-1-(pyridin-2-yl)-7-styrylindoline (3v)



Following the general reaction procedure A, **3v** was obtained as a yellow oil (32.6 mg, 0.09 mmol, Yield: 62%); ¹H NMR (400 MHz, CDCl₃) δ 8.36 – 8.24 (m, 1H), 7.58 (d, *J* = 2.0 Hz, 1H), 7.39 (ddd, *J*


δ = 8.5, 7.3, 2.0 Hz, 1H), 7.28 – 7.11 (m, 6H), 6.94 (d, J = 16.3 Hz, 1H), 6.77 (m, 1H), 6.77 (d, J = 8.5 Hz, 1H), 6.64 (d, J = 16.3 Hz, 1H), 4.36 (t, J = 8.0 Hz, 2H), 3.07 (t, J = 8.0 Hz, 2H); ^{13}C NMR (101 MHz, CDCl_3) δ 157.57, 148.00, 142.32, 137.47, 137.11, 136.90 \times 2, 128.74, 128.55 \times 2, 127.67, 127.12, 126.70, 126.43, 125.13 \times 2, 116.06, 115.41, 111.24, 54.32, 29.12; HRMS (ESI): m/z calculated for $[\text{C}_{21}\text{H}_{18}\text{BrN}_2]^+ [\text{M} + \text{H}]^+$: 377.0653, Found: 377.0650; FTIR (NaCl): ν 3055, 2958, 1589, 1469, 1431, 1323, 1153, 1056, 964, 910, 864, 732 cm^{-1}

(E)-5-fluoro-1-(pyridin-2-yl)-7-styrylindoline (3w)




Following the general reaction procedure A, **3w** was obtained as a yellow solid (38.1 mg, 0.12 mmol, Yield: 86%); m.p. = 163–165 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.29 – 8.27 (m, 1H), 7.46 – 7.33 (m, 1H), 7.28 – 7.11 (m, 6H), 6.95 (d, J = 16.3 Hz, 1H), 6.91 – 6.84 (m, 1H), 6.81 – 6.65 (m, 3H), 4.40 (t, J = 7.9 Hz, 2H), 3.04 (t, J = 7.9 Hz, 2H); ^{13}C NMR (101 MHz, CDCl_3) δ 159.50 (d, J = 240.6 Hz), 158.19, 147.97, 139.39, 137.42 (d, J = 8.9 Hz), 137.09, 136.88, 128.80, 128.54 \times 2, 127.67, 126.45 \times 2, 126.19 (d, J = 8.9 Hz), 125.31 (d, J = 2.3 Hz), 115.68, 111.45 (d, J = 24.4 Hz), 110.65, 109.94 (d, J = 24.4 Hz), 54.62, 29.63; ^{19}F NMR (376 MHz, CDCl_3) δ -120.67; HRMS (ESI): m/z calculated for $[\text{C}_{21}\text{H}_{18}\text{FN}_2]^+ [\text{M} + \text{H}]^+$: 317.1454, Found: 317.1453; FTIR (NaCl): ν 2954, 2916, 2848, 1463, 1431, 1263, 1176 cm^{-1}

(E)-5-methoxy-2-methyl-1-(pyridin-2-yl)-7-styrylindoline (3x)




Following the general reaction procedure A, **3x** was obtained as a yellow solid (45.0 mg, 0.13 mmol, Yield: 94%); m.p. = 122–124 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.28 – 8.26 (m, 1H), 7.34 (ddd, J = 8.5, 7.2, 2.0 Hz, 1H), 7.27 – 7.13 (m, 5H), 7.02 – 6.97 (m, 2H), 6.83 – 6.75 (m, 2H), 6.72 – 6.63 (m, 2H), 4.83 (qd, J = 8.5, 6.6 Hz, 1H), 3.85 (s, 3H), 3.41 (dd, J = 15.5, 8.3 Hz, 1H), 2.45 (d, J = 15.5 Hz, 1H), 1.45 (d, J = 6.6 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 158.38, 156.41, 147.98, 137.45, 136.75, 135.94 \times 2, 128.48 \times 2, 127.91, 127.39, 126.40 \times 3, 126.17, 115.24, 111.63, 109.93, 108.14, 61.87, 55.71, 37.05, 22.31; HRMS (ESI): m/z calculated for $[\text{C}_{23}\text{H}_{23}\text{N}_2\text{O}]^+ [\text{M} + \text{H}]^+$: 343.1810, Found: 343.1807; FTIR (NaCl): ν 3417, 2956, 2918, 1593, 1469, 1429, 1265, 1199, 1143, 1043, 736, 692 cm^{-1}

(E)-4-(2-(5-methoxy-2-methyl-1-(pyridin-2-yl)indolin-7-yl)vinyl)phenyl acetate (3y)




Following the general reaction procedure A, **3y** was obtained as a yellow oil (42.6 mg, 0.11 mmol, Yield: 76%); ¹H NMR (400 MHz, CDCl₃) δ 8.27 – 8.25 (m, 1H), 7.35 (ddd, *J* = 8.9, 7.2, 2.0 Hz, 1H), 7.25 – 7.22 (m, 2H), 7.03 – 6.88 (m, 4H), 6.83 – 6.61 (m, 4H), 4.85 – 4.78 (m, 1H), 3.85 (s, 3H), 3.41 (dd, *J* = 15.6, 8.3 Hz, 1H), 2.45 (d, *J* = 15.6 Hz, 1H), 2.27 (s, 3H), 1.45 (d, *J* = 6.6 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 169.41, 158.39, 156.41, 149.87, 148.03, 136.79, 135.99, 135.96, 135.29, 127.32 × 2, 126.82, 126.44, 126.23, 121.59 × 2, 115.31, 111.72, 109.89, 108.14, 61.90, 55.73, 37.05, 22.34, 21.06; HRMS (ESI): m/z calculated for [C₂₅H₂₅N₂O₃]⁺ [M + H]⁺: 401.1865, Found: 401.1863; FTIR (NaCl): ν 3429, 3417, 2843, 1761, 1587, 1504, 1469, 1429, 1193, 1165, 1143 cm⁻¹

(E)-5-methoxy-2-methyl-7-(2-methylstyryl)-1-(pyridin-2-yl)indoline (**3z**)



Following the general reaction procedure A, **3z** was obtained as a yellow solid (40.4 mg, 0.11 mmol, Yield: 81%); m.p. = 88-90 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.28 – 8.26 (m, 1H), 7.39 – 7.31 (m, 1H), 7.22 – 7.18 (m, 2H), 7.13 – 6.96 (m, 4H), 6.84 – 6.76 (m, 1H), 6.72 – 6.67 (m, 3H), 4.88 – 4.81 (m, 1H), 3.86 (s, 3H), 3.42 (dd, *J* = 15.6, 8.3 Hz, 1H), 2.46 (d, *J* = 15.6 Hz, 1H), 2.28 (s, 3H), 1.45 (d, *J* = 6.6 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 158.29, 156.49, 148.09, 136.77, 136.49, 136.08, 135.88, 135.72, 130.22, 127.45, 127.37, 127.14, 126.29, 126.07, 125.40, 115.33, 111.19, 110.12, 109.33, 61.92, 55.80, 37.09, 22.40, 19.75; HRMS (ESI): m/z calculated for [C₂₄H₂₅N₂O]⁺ [M + H]⁺: 357.1967, Found: 357.1968; FTIR (NaCl): ν 3419, 1595, 1467, 1429, 1334, 1145, 1043, 968 cm⁻¹


(E)-5-bromo-7-(3-methylstyryl)-1-(pyridin-2-yl)indoline (**3aa**)



Following the general reaction procedure A, **3aa** was obtained as a yellow solid (43.7 mg, 0.11 mmol, Yield: 80%); m.p. = 99-101 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.38 – 8.30 (m, 1H), 7.60 (d, *J* = 1.5 Hz, 1H), 7.43 (td, *J* = 7.8, 1.5 Hz, 1H), 7.28 – 7.27 (m, 1H), 7.16 (t, *J* = 7.8 Hz, 1H), 7.04 – 7.02 (m, 3H), 6.95 (d, *J* = 16.3 Hz, 1H), 6.80 (ddd, *J* = 7.8, 5.0, 0.7 Hz, 1H), 6.73 (d, *J* = 8.4 Hz, 1H), 6.65 (d, *J* = 16.3 Hz, 1H), 4.40 (t, *J* = 8.0 Hz, 2H), 3.10 (t, *J* = 8.0 Hz, 2H), 2.30 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 157.62, 148.04, 142.31, 138.10, 137.48, 137.09, 136.90, 128.81, 128.50, 128.45, 127.29, 127.08, 126.63, 126.51, 124.98, 123.57, 116.00, 115.40, 111.26, 54.30, 29.14, 21.29; HRMS (ESI): m/z calculated for [C₂₂H₂₀BrN₂]⁺ [M + H]⁺: 391.0810, Found: 391.0812; FTIR (NaCl): ν 3431, 3419, 2916,


1591, 1469, 1433, 1323, 1265, 964 cm⁻¹

(S, E)-methyl 2-acetamido-3-(1-(pyridin-2-yl)-2-styryl-1H-indol-3-yl)propanoate (5a)




Following the general reaction procedure A, **5a** was obtained as a colorless oil (38.5 mg, 0.11 mmol, Yield: 81%); ¹H NMR (400 MHz, CDCl₃) δ 8.74 (dd, *J* = 4.9, 0.9 Hz, 1H), 7.87 (td, *J* = 7.7, 1.8 Hz, 1H), 7.57 (dd, *J* = 7.7, 1.8 Hz, 1H), 7.44 (dd, *J* = 7.7, 1.8 Hz, 1H), 7.38 (ddd, *J* = 7.7, 4.9, 0.9 Hz, 1H), 7.35 – 7.30 (m, 5H), 7.27 – 7.17 (m, 3H), 7.10 (d, *J* = 16.7 Hz, 1H), 6.37 (d, *J* = 16.7 Hz, 1H), 6.14 (d, *J* = 7.9 Hz, NH), 5.02 (dt, *J* = 7.9, 5.6 Hz, 1H), 3.67 – 3.50 (m, 5H), 1.86 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 172.21, 169.72, 152.14, 149.52, 138.35, 138.34, 136.91, 134.89, 132.24, 129.00, 128.71 × 2, 127.91, 126.21 × 2, 123.82, 122.36, 122.34, 121.19, 118.68, 116.69, 112.71, 110.90, 52.83, 52.48, 27.42, 23.13; HRMS (ESI): m/z calculated for [C₂₇H₂₆N₃O₃]⁺ [M + H]⁺: 440.1974, Found: 440.1971; FTIR (NaCl): ν 3417, 3052, 1745, 1645, 1469, 1371, 1265, 1226, 698 cm⁻¹

(S, E)-methyl 2-acetamido-3-(2-phenyl-1-(pyridin-2-yl)-7-styryl-1H-indol-3-yl)propanoate (5b)



Following the general reaction procedure A, **5b** was obtained as a colorless oil (31.0 mg, 0.06 mmol, Yield: 43%); ¹H NMR (400 MHz, CDCl₃) δ 8.62 – 8.50 (m, 1H), 7.64 (d, *J* = 7.7 Hz, 1H), 7.58 (td, *J* = 7.7, 1.9 Hz, 1H), 7.44 (d, *J* = 7.7 Hz, 1H), 7.36 – 7.11 (m, 10H), 7.02 – 7.00 (m, 3H), 6.80 (d, *J* = 16.0 Hz, 1H), 6.53 (d, *J* = 16.0 Hz, 1H), 5.77 (d, *J* = 7.8 Hz, NH), 4.96 – 4.72 (m, 1H), 3.59 – 3.26 (m, 5H), 1.76 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 172.13, 169.63, 153.06, 148.96, 139.80, 137.75, 137.41, 134.80, 131.40, 130.96 × 2, 129.52, 129.34, 128.36 × 2, 128.26 × 2, 128.07, 127.22, 126.17 × 2, 125.63, 124.58, 123.29, 123.10, 121.91, 121.06, 118.58, 109.30, 52.59, 52.14, 26.54, 23.04; HRMS (ESI): m/z calculated for [C₃₃H₃₀N₃O₃]⁺ [M + H]⁺: 516.2287, Found: 516.2283; FTIR (NaCl): ν 3583, 3425, 3055, 2918, 2247, 1745, 1585, 1469, 1371, 1265, 1217, 964 cm⁻¹


(E)-2-methyl-7-styrylindoline (3p')



Following the reported method^[3], **3p'** was obtained as a colorless oil (28.6 mg, 0.12 mmol, Yield: 81%); ¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, *J* = 7.7 Hz, 2H), 7.34 (t, *J* = 7.7 Hz, 2H), 7.23 (dt, *J* = 16.9, 7.7 Hz, 2H), 7.11 – 6.92 (m, 3H), 6.72 (t, *J* = 7.7 Hz, 1H), 4.29 – 3.78 (m, 1H), 3.17 (dd, *J* = 15.4, 7.8 Hz,


1H), 2.67 (dd, J = 15.4, 7.8 Hz, 1H), 1.33 (d, J = 6.2 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 148.68, 137.82, 129.69, 128.61 \times 2, 128.54, 127.28, 126.24 \times 2, 125.43, 125.22, 123.84, 119.36, 119.05, 55.29, 37.68, 22.38; HRMS (ESI): m/z calculated for $[\text{C}_{17}\text{H}_{18}\text{N}]^+ [\text{M} + \text{H}]^+$: 236.1439, Found: 236.1433; FTIR (NaCl): ν 3369, 2958, 1629, 1597, 1452, 1257, 1058, 960 cm^{-1}

1-(pyridin-2-yl)-7-((triisopropylsilyl)ethynyl)indoline (6a)




Following the general reaction procedure C, **6a** was obtained as a yellow solid (40.6 mg, 0.11 mmol, Yield: 77%); m.p. = 44–46 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.28 (dd, J = 5.0, 1.7 Hz, 1H), 7.50 – 7.42 (m, 1H), 7.28 (d, J = 7.3 Hz, 1H), 7.18 (dd, J = 7.3, 0.9 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 6.86 (t, J = 7.3 Hz, 1H), 6.77 (dd, J = 7.3, 5.0 Hz, 1H), 4.34 (t, J = 8.2 Hz, 2H), 3.07 (t, J = 8.2 Hz, 2H), 1.00 – 0.85 (m, 21H); ^{13}C NMR (101 MHz, CDCl_3) δ 156.04, 147.57, 146.07, 136.12, 134.84, 132.59, 125.10, 121.50, 115.93, 112.88, 109.44, 104.40, 99.74, 53.83, 28.73, 18.51 \times 6, 11.11 \times 3; HRMS (ESI): m/z calculated for $[\text{C}_{24}\text{H}_{33}\text{N}_2\text{Si}]^+ [\text{M} + \text{H}]^+$: 377.2413, Found: 377.2417; FTIR (NaCl): ν 3410, 2941, 2862, 2144, 1705, 1593, 1579, 1469, 1433, 1381, 1153, 1064, 883, 673 cm^{-1}

2-methyl-1-(pyridin-2-yl)-7-((triisopropylsilyl)ethynyl)indoline (6b)



Following the general reaction procedure C, **6b** was obtained as a yellow solid (44.8 mg, 0.11 mmol, Yield: 82%); m.p. = 92–94 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.27 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.44 (ddd, J = 8.5, 7.2, 1.9 Hz, 1H), 7.29 (d, J = 7.2 Hz, 1H), 7.18 (dd, J = 7.2, 0.9 Hz, 1H), 6.91 (d, J = 8.5 Hz, 1H), 6.87 (t, J = 7.2 Hz, 1H), 6.76 (ddd, J = 7.2, 4.9, 0.9 Hz, 1H), 4.68 (dq, J = 8.7, 6.5, 1.9 Hz, 1H), 3.41 (dd, J = 15.5, 8.7 Hz, 1H), 2.50 (dd, J = 15.5, 1.9 Hz, 1H), 1.43 (d, J = 6.5 Hz, 3H), 1.02 – 0.84 (m, 21H); ^{13}C NMR (101 MHz, CDCl_3) δ 155.88, 147.75, 145.23, 136.07, 133.61, 132.41, 125.52, 121.58, 115.99, 112.39, 110.28, 104.48, 99.21, 61.42, 36.54, 22.31, 18.55 \times 3, 18.50 \times 3, 11.14 \times 3; HRMS (ESI): m/z calculated for $[\text{C}_{25}\text{H}_{35}\text{N}_2\text{Si}]^+ [\text{M} + \text{H}]^+$: 391.2570, Found: 391.2563; FTIR (NaCl): ν 3446, 3412, 2146, 1593, 1579, 1469, 1435, 1381, 883, 769 cm^{-1}


2-phenyl-1-(pyridin-2-yl)-7-((triisopropylsilyl)ethynyl)indoline (6c)



Following the general reaction procedure C, **6c** was obtained as a white solid (56.4 mg, 0.12 mmol, Yield: 89%); m.p. = 96–98 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.24 (ddd, J = 5.0, 1.9, 0.8 Hz, 1H), 7.44 (ddd, J = 8.5, 7.2, 1.9 Hz, 1H), 7.42 – 7.39 (m, 2H), 7.35 – 7.17 (m, 4H), 7.09 (dd, J = 7.2, 0.8 Hz, 1H), 6.92 – 6.84 (m, 2H), 6.76 (ddd, J = 7.2, 5.0, 0.8 Hz, 1H), 5.64 (d, J = 8.7 Hz, 1H), 3.82 (dd, J = 15.5, 8.7 Hz, 1H), 2.91 (dd, J = 15.5, 1.4 Hz, 1H), 1.05 – 0.84 (m, 21H); ^{13}C NMR (101 MHz, CDCl_3) δ


155.91, 147.88, 146.06, 143.93, 136.31, 132.68, 132.19, 128.48 × 2, 126.92, 125.65 × 2, 125.28, 122.27, 116.19, 111.75, 110.84, 104.34, 99.08, 67.79, 38.69, 18.54 × 3, 18.46 × 3, 11.14 × 3; HRMS (ESI): m/z calculated for [C₃₀H₃₇N₂Si]⁺ [M + H]⁺: 453.2726, Found: 453.2725; FTIR (NaCl): ν 3412, 2941, 2864, 2146, 1797, 1583, 1469, 1433, 1379, 1253, 1153, 1060, 883, 771 cm⁻¹

3-methyl-1-(pyridin-2-yl)-7-((triisopropylsilyl)ethynyl)indoline (6d)




Following the general reaction procedure C, **6d** was obtained as a yellow oil (34.4 mg, 0.09 mmol, Yield: 63%); ¹H NMR (400 MHz, CDCl₃) δ 8.28 (d, *J* = 5.0 Hz, 1H), 7.46 (ddd, *J* = 8.4, 7.3, 1.9 Hz, 1H), 7.29 (d, *J* = 8.4 Hz, 1H), 7.14 (d, *J* = 7.3 Hz, 1H), 6.96 (d, *J* = 8.4 Hz, 1H), 6.89 (t, *J* = 7.3 Hz, 1H), 6.76 (dd, *J* = 7.3, 5.0 Hz, 1H), 4.48 (dd, *J* = 10.7, 8.7 Hz, 1H), 3.89 (dd, *J* = 10.7, 7.1 Hz, 1H), 3.46 – 3.32 (m, 1H), 1.28 (d, *J* = 6.9 Hz, 3H), 0.97 – 0.83 (m, 21H); ¹³C NMR (101 MHz, CDCl₃) δ 156.07, 147.62, 145.58, 140.01, 136.12, 132.68, 123.92, 121.62, 115.83, 112.61, 109.43, 104.29, 99.63, 61.72, 35.44, 19.33, 18.50 × 6, 11.10 × 3; HRMS (ESI): m/z calculated for [C₂₅H₃₅N₂Si]⁺ [M + H]⁺: 391.2570, Found: 391.2575; FTIR (NaCl): ν 3583, 3412, 2956, 2916, 2144, 1703, 1593, 1435, 1325, 1153, 1074, 997, 883, 713 cm⁻¹

4-methyl-1-(pyridin-2-yl)-7-((triisopropylsilyl)ethynyl)indoline (6e)



Following the general reaction procedure C, **6e** was obtained as a yellow solid (37.2 mg, 0.10 mmol, Yield: 68%); m.p. = 55–57 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.37 – 8.22 (m, 1H), 7.45 (ddd, *J* = 8.4, 7.9, 2.0 Hz, 1H), 7.21 (d, *J* = 7.9 Hz, 1H), 6.96 (d, *J* = 8.4 Hz, 1H), 6.76 (ddd, *J* = 7.9, 5.0, 0.8 Hz, 1H), 6.70 (d, *J* = 7.9 Hz, 1H), 4.35 (t, *J* = 8.3 Hz, 2H), 2.97 (t, *J* = 8.3 Hz, 2H), 2.24 (s, 3H), 0.99 – 0.82 (m, 21H); ¹³C NMR (101 MHz, CDCl₃) δ 156.06, 147.56, 145.62, 135.98, 134.98, 133.12, 132.51, 122.92, 115.77, 112.87, 106.85, 104.50, 98.75, 53.55, 27.45, 18.85, 18.49 × 6, 11.11 × 3; HRMS (ESI): m/z calculated for [C₂₅H₃₅N₂Si]⁺ [M + H]⁺: 391.2570, Found: 391.2561; FTIR (NaCl): ν 2941, 2864, 2304, 2148, 1593, 1573, 1469, 1433, 1153, 894 cm⁻¹


4-bromo-1-(pyridin-2-yl)-7-((triisopropylsilyl)ethynyl)indoline (6f)



Following the general reaction procedure C, **6f** was obtained as a yellow oil (46.4 mg, 0.10 mmol, Yield: 73%); ¹H NMR (400 MHz, CDCl₃) δ 8.29 (dd, *J* = 4.9, 1.1 Hz, 1H), 7.49 (ddd, *J* = 8.4, 7.2, 1.1


Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), 6.98 (d, J = 8.4 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 6.81 (ddd, J = 7.2, 4.9, 1.1 Hz, 1H), 4.34 (t, J = 8.4 Hz, 2H), 3.09 (t, J = 8.4 Hz, 2H), 0.94 – 0.91 (m, 21H); ^{13}C NMR (101 MHz, CDCl_3) δ 155.59, 147.72, 146.81, 136.17, 134.92, 134.01, 124.23, 119.92, 116.61, 113.19, 107.86, 103.47, 100.70, 53.08, 30.18, 18.47 \times 6, 11.05 \times 3; HRMS (ESI): m/z calculated for $[\text{C}_{24}\text{H}_{32}\text{BrN}_2\text{Si}]^+ [\text{M} + \text{H}]^+$: 455.1518, Found: 455.1511; FTIR (NaCl): ν 2953, 2916, 2146, 1732, 1568, 1435, 1317, 1153, 1062, 993, 883, 738 cm^{-1}

5-bromo-1-(pyridin-2-yl)-7-((triisopropylsilyl)ethynyl)indoline (6g)




Following the general reaction procedure C, **6g** was obtained as a yellow oil (49.6 mg, 0.11 mmol, Yield: 78%); ^1H NMR (400 MHz, CDCl_3) δ 8.37 – 8.20 (m, 1H), 7.48 (ddd, J = 8.4, 7.2, 2.0 Hz, 1H), 7.38 (d, J = 2.0 Hz, 1H), 7.25 (s, 1H), 6.90 (d, J = 8.4 Hz, 1H), 6.80 (ddd, J = 7.2, 5.0, 0.8 Hz, 1H), 4.32 (t, J = 8.3 Hz, 2H), 3.07 (t, J = 8.3 Hz, 2H), 0.98 – 0.83 (m, 21H); ^{13}C NMR (101 MHz, CDCl_3) δ 155.63, 147.75, 145.33, 136.95, 136.22, 134.48, 128.15, 116.41, 112.95, 112.85, 110.68, 102.85, 101.27, 53.99, 28.51, 18.49 \times 6, 11.06 \times 3; HRMS (ESI): m/z calculated for $[\text{C}_{24}\text{H}_{32}\text{BrN}_2\text{Si}]^+ [\text{M} + \text{H}]^+$: 455.1518, Found: 455.1516; FTIR (NaCl): ν 3001, 2954, 2862, 2146, 1705, 1593, 1573, 1469, 1435, 1319, 1153, 997, 881, 866, 717 cm^{-1}

5-fluoro-1-(pyridin-2-yl)-7-((triisopropylsilyl)ethynyl)indoline (6h)



Following the general reaction procedure C, **6h** was obtained as a yellow solid (40.8 mg, 0.10 mmol, Yield: 74%); m.p. = 44–46 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.28 – 8.26 (m, 1H), 7.49 – 7.44 (m, 1H), 7.01 – 6.85 (m, 3H), 6.77 (dd, J = 6.9, 5.2 Hz, 1H), 4.35 (t, J = 8.2 Hz, 2H), 3.05 (t, J = 8.2 Hz, 2H), 0.94 – 0.94 (m, 21H); ^{13}C NMR (101 MHz, CDCl_3) δ 157.66 (d, J = 240.6 Hz), 156.16, 147.68, 142.58, 136.95 (d, J = 8.9 Hz), 136.20, 117.64 (d, J = 24.2 Hz), 115.91, 113.30 (d, J = 24.2 Hz), 112.31, 110.11 (d, J = 10.0 Hz), 103.08 (d, J = 2.5 Hz), 100.66, 54.27, 29.06 (d, J = 1.9 Hz), 18.45 \times 6, 11.04 \times 3; ^{19}F NMR (376 MHz, CDCl_3) δ -122.41; HRMS (ESI): m/z calculated for $[\text{C}_{24}\text{H}_{32}\text{FN}_2\text{Si}]^+ [\text{M} + \text{H}]^+$: 395.2319, Found: 395.2308; FTIR (NaCl): ν 3051, 2941, 2864, 2140, 1585, 1465, 1433, 1265, 1124, 696 cm^{-1}


6-chloro-1-(pyridin-2-yl)-7-((triisopropylsilyl)ethynyl)indoline (6i)



Following the general reaction procedure C, **6i** was obtained as a yellow oil (28.7 mg, 0.07 mmol, Yield: 50%); ^1H NMR (400 MHz, CDCl_3) δ 8.29 (dd, J = 4.9, 1.3 Hz, 1H), 7.53 – 7.44 (m, 1H), 7.06 (d, J = 7.8 Hz, 1H), 6.98 (d, J = 7.8 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.81 (dd, J = 7.8, 4.9 Hz, 1H), 4.36


(t, $J = 8.3$ Hz, 2H), 3.04 (t, $J = 8.3$ Hz, 2H), 0.99 – 0.82 (m, 21H); ^{13}C NMR (101 MHz, CDCl_3) δ 155.63, 147.83, 147.67, 136.06, 135.78, 133.08, 124.74, 122.02, 116.45, 113.25, 109.48, 106.20, 100.39, 54.57, 28.28, 18.46×6 , 11.03×3 ; HRMS (ESI): m/z calculated for $[\text{C}_{24}\text{H}_{32}\text{ClN}_2\text{Si}]^+ [\text{M} + \text{H}]^+$: 411.2023, Found: 411.2017; FTIR (NaCl): ν 2954, 2891, 2148, 1699, 1587, 1469, 1427, 1309, 1232, 1062, 995, 883, 804 cm^{-1}

1-(pyridin-2-yl)-7-((triethylsilyl)ethynyl)indoline (6j)




Following the general reaction procedure D, **6j** was obtained as a brown solid (33.7 mg, 0.10 mmol, Yield: 72%); m.p. = 60–62 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.30 (ddd, $J = 5.0, 2.0, 0.8$ Hz, 1H), 7.49 (ddd, $J = 8.4, 7.6, 2.0$ Hz, 1H), 7.27 – 7.25 (m, 1H), 7.17 (dd, $J = 7.6, 0.8$ Hz, 1H), 6.95 (d, $J = 8.4$ Hz, 1H), 6.84 (t, $J = 7.6$ Hz, 1H), 6.80 (ddd, $J = 7.6, 5.0, 0.8$ Hz, 1H), 4.33 (t, $J = 8.4$ Hz, 2H), 3.07 (t, $J = 8.3$ Hz, 2H), 0.82 (t, $J = 7.9$ Hz, 9H), 0.42 (q, $J = 7.9$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 155.75, 147.51, 146.20, 135.74, 134.60, 132.23, 125.14, 121.29, 115.96, 113.22, 108.80, 103.58, 100.84, 53.69, 28.63, 7.28×3 , 4.08×3 ; HRMS (ESI): m/z calculated for $[\text{C}_{21}\text{H}_{27}\text{N}_2\text{Si}]^+ [\text{M} + \text{H}]^+$: 335.1944, Found: 335.1938; FTIR (NaCl): ν 3583, 2954, 2873, 2144, 1593, 1579, 1469, 1433, 1377, 1263, 1016 cm^{-1}

7-((tert-butyldimethylsilyl)ethynyl)-1-(pyridin-2-yl)indoline (6k)



Following the general reaction procedure D, **6k** was obtained as a brown solid (38.8 mg, 0.12 mmol, Yield: 83%); m.p. = 86–88 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.34 – 8.25 (m, 1H), 7.49 (ddd, $J = 8.6, 7.6, 2.0$ Hz, 1H), 7.25 (d, $J = 7.6$ Hz, 1H), 7.17 (dd, $J = 7.6, 0.8$ Hz, 1H), 6.94 (d, $J = 8.6$ Hz, 1H), 6.84 (t, $J = 7.6$ Hz, 1H), 6.80 (ddd, $J = 7.6, 5.0, 0.8$ Hz, 1H), 4.33 (t, $J = 8.3$ Hz, 2H), 3.08 (t, $J = 8.3$ Hz, 2H), 0.79 (s, 9H), -0.09 (s, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 155.81, 147.51, 146.25, 135.94, 134.58, 132.13, 125.18, 121.32, 116.03, 113.23, 108.76, 103.18, 101.51, 53.75, 28.65, 25.98×3 , 16.42, -4.89 $\times 2$; HRMS (ESI): m/z calculated for $[\text{C}_{21}\text{H}_{27}\text{N}_2\text{Si}]^+ [\text{M} + \text{H}]^+$: 335.1944, Found: 335.1936; FTIR (NaCl): ν 3053, 2954, 2854, 2304, 2146, 1593, 1581, 1469, 1433, 1265, 894, 704 cm^{-1}


7-((tert-butyldiphenylsilyl)ethynyl)-1-(pyridin-2-yl)indoline (6l)



Following the general reaction procedure D, **6l** was obtained as a yellow oil (47.5 mg, 0.10 mmol, Yield: 74%); ^1H NMR (400 MHz, CDCl_3) δ 8.20 (d, $J = 5.2$ Hz, 1H), 7.57 (dd, $J = 7.6, 1.4$ Hz, 4H), 7.42 – 7.26 (m, 7H), 7.21 (dd, $J = 7.6, 0.9$ Hz, 1H), 7.17 – 7.11 (m, 1H), 7.00 (d, $J = 8.4$ Hz, 1H), 6.89 (t, $J = 7.6$ Hz, 1H), 6.55 (dd, $J = 7.6, 5.2$ Hz, 1H), 4.33 (t, $J = 8.3$ Hz, 2H), 3.09 (t, $J = 8.3$ Hz, 2H), 0.96 (s, 9H); ^{13}C NMR (101 MHz, CDCl_3) δ 155.67, 147.53, 146.17, 136.21×2 , 135.52×4 , 134.77,


133.37, 132.71, 129.20 × 2, 127.54 × 4, 125.58, 121.38, 116.26, 112.76, 108.56, 106.49, 98.22, 53.79, 28.61, 27.02 × 3, 18.48; HRMS (ESI): m/z calculated for [C₃₁H₃₁N₂Si]⁺ [M + H]⁺: 459.2257, Found: 459.2254; FTIR (NaCl): ν 3444, 3068, 2956, 2927, 2854, 2146, 1699, 1593, 1581, 1469, 1433, 1323, 1111, 819, 700 cm⁻¹

7-((tert-butyldiphenylsilyl)ethynyl)-2-phenyl-1-(pyridin-2-yl)indoline (6m)




Following the general reaction procedure D, **6m** was obtained as a white solid (60.6 mg, 0.11 mmol, Yield: 81%); m.p. = 194–196 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.21 – 8.07 (m, 1H), 7.69 – 7.59 (m, 4H), 7.46 – 7.42 (m, 3H), 7.39 – 7.19 (m, 10H), 7.15 (d, J = 7.6 Hz, 1H), 6.92 (t, J = 7.6 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 6.57 (dd, J = 7.6, 5.0 Hz, 1H), 5.62 (d, J = 8.7 Hz, 1H), 3.86 (dd, J = 15.5, 8.7 Hz, 1H), 2.96 (d, J = 15.7 Hz, 1H), 0.95 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 155.89, 147.92, 146.41, 143.91, 136.56, 135.60 × 4, 133.50, 133.33, 132.68, 132.44, 129.24 × 2, 128.61 × 2, 127.57 × 4, 127.05, 125.83, 125.69 × 2, 122.25, 116.64, 111.83, 110.14, 106.71, 97.58, 68.08, 38.75, 26.98 × 3, 18.58; HRMS (ESI): m/z calculated for [C₃₇H₃₅N₂Si]⁺ [M + H]⁺: 535.2570, Found: 535.2563; FTIR (NaCl): ν 3052, 2985, 2304, 2148, 1469, 1431, 1265, 894, 702 cm⁻¹

7-((tert-butyldiphenylsilyl)ethynyl)-3-methyl-1-(pyridin-2-yl)indoline (6n)



Following the general reaction procedure D, **6n** was obtained as a yellow oil (49.6 mg, 0.11 mmol, Yield: 75%); ¹H NMR (400 MHz, CDCl₃) δ 8.27 – 8.08 (m, 1H), 7.59 – 7.56 (m, 4H), 7.41 (d, J = 7.6 Hz, 1H), 7.38 – 7.25 (m, 6H), 7.21 – 7.09 (m, 2H), 7.00 (d, J = 8.4 Hz, 1H), 6.92 (t, J = 7.6 Hz, 1H), 6.54 (ddd, J = 7.6, 5.0, 0.8 Hz, 1H), 4.48 (dd, J = 10.7, 8.7 Hz, 1H), 3.91 (dd, J = 10.7, 7.1 Hz, 1H), 3.47 – 3.34 (m, 1H), 1.30 (d, J = 7.1 Hz, 3H), 0.96 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 155.81, 147.57, 145.78, 140.01, 136.29, 135.53 × 4, 133.41, 133.36, 132.83, 129.21 × 2, 127.55 × 4, 124.46, 121.57, 116.22, 112.58, 108.58, 106.51, 98.16, 61.74, 35.36, 27.03 × 3, 19.39, 18.48; HRMS (ESI): m/z calculated for [C₃₂H₃₃N₂Si]⁺ [M + H]⁺: 473.2413, Found: 473.2414; FTIR (NaCl): ν 3070, 2927, 2146, 1581, 1469, 1429, 1325, 1300, 1251, 1109, 908, 819 cm⁻¹


7-((tert-butyldiphenylsilyl)ethynyl)-4-methyl-1-(pyridin-2-yl)indoline (6o)



Following the general reaction procedure D, **6o** was obtained as a yellow oil (60.2 mg, 0.13 mmol, Yield: 91%); ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, J = 5.1 Hz, 1H), 7.58 – 7.58 (m, 4H), 7.41 – 7.21


(m, 7H), 7.18 – 7.10 (m, 1H), 7.00 (d, J = 8.4 Hz, 1H), 6.73 (d, J = 7.9 Hz, 1H), 6.54 (dd, J = 7.9, 5.1 Hz, 1H), 4.35 (t, J = 8.3 Hz, 2H), 2.99 (t, J = 8.3 Hz, 2H), 2.26 (s, 3H), 0.95 (s, 9H); ^{13}C NMR (101 MHz, CDCl_3) δ 155.83, 147.52, 145.84, 136.16 \times 2, 135.58, 135.53 \times 4, 133.51, 133.14, 132.67, 129.15 \times 2, 127.51 \times 4, 122.90, 116.14, 112.79, 106.78, 106.04, 97.32, 53.58, 27.39, 27.02 \times 3, 18.91, 18.48; HRMS (ESI): m/z calculated for $[\text{C}_{32}\text{H}_{33}\text{N}_2\text{Si}]^+$ [M + H] $^+$: 473.2413, Found: 473.2404; FTIR (NaCl): ν 3070, 2954, 2146, 1693, 1593, 1446, 1381, 1111, 908, 819 cm^{-1}

7-(3,3-dimethylbut-1-yn-1-yl)-1-(pyridin-2-yl)indoline (6p)




Following the general reaction procedure D, **6p** was obtained as a yellow solid (27.8 mg, 0.10 mmol, Yield: 72%); m.p. = 82–84 °C; ^1H NMR (500 MHz, CDCl_3) δ 8.31 (dd, J = 5.0, 1.1 Hz, 1H), 7.50 (ddd, J = 8.4, 7.8, 1.9 Hz, 1H), 7.18 (d, J = 7.8 Hz, 1H), 7.13 (dd, J = 7.8, 1.1 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.84 (t, J = 7.8 Hz, 1H), 6.79 (ddd, J = 7.8, 5.0, 1.1 Hz, 1H), 4.33 (t, J = 8.2 Hz, 2H), 3.07 (t, J = 8.2 Hz, 2H), 0.99 (s, 9H); ^{13}C NMR (126 MHz, CDCl_3) δ 156.19, 147.53, 145.88, 135.85, 134.45, 131.49, 124.23, 121.48, 115.68, 113.33, 109.74, 107.17, 77.10, 53.74, 30.54 \times 3, 28.87, 28.00; HRMS (ESI): m/z calculated for $[\text{C}_{19}\text{H}_{21}\text{N}_2]^+$ [M + H] $^+$: 277.1705, Found: 277.1702; FTIR (NaCl): ν 3419, 2966, 2922, 2108, 1635, 1593, 1581, 1469, 1433, 1327, 1151, 987 cm^{-1}

7-(3,3-dimethylbut-1-yn-1-yl)-3-methyl-1-(pyridin-2-yl)indoline (6q)



Following the general reaction procedure D, **6q** was obtained as a yellow oil (30.1 mg, 0.10 mmol, Yield: 74%); ^1H NMR (400 MHz, CDCl_3) δ 8.30 (ddd, J = 5.0, 1.9, 0.8 Hz, 1H), 7.50 (ddd, J = 8.5, 7.1, 1.9 Hz, 1H), 7.19 (d, J = 8.5 Hz, 1H), 7.10 (dt, J = 7.1, 0.8 Hz, 1H), 6.95 – 6.84 (m, 2H), 6.78 (ddd, J = 7.1, 5.0, 0.8 Hz, 1H), 4.46 (dd, J = 10.7, 8.7 Hz, 1H), 3.88 (dd, J = 10.7, 7.1 Hz, 1H), 3.44 – 3.35 (m, 1H), 1.28 (d, J = 6.9 Hz, 3H), 0.99 (s, 9H); ^{13}C NMR (101 MHz, CDCl_3) δ 156.29, 147.57, 145.47, 139.66, 135.84, 131.53, 123.02, 121.59, 115.57, 113.04, 109.70, 107.08, 77.04, 61.64, 35.56, 30.51 \times 3, 27.96, 19.36; HRMS (ESI): m/z calculated for $[\text{C}_{20}\text{H}_{23}\text{N}_2]^+$ [M + H] $^+$: 291.1961, Found: 291.1859; FTIR (NaCl): ν 2964, 2868, 2218, 1728, 1579, 1429, 1220, 1056, 910 cm^{-1}


5-bromo-7-(3,3-dimethylbut-1-yn-1-yl)-1-(pyridin-2-yl)indoline (6r)



Following the general reaction procedure D, **6r** was obtained as a yellow oil (43.6 mg, 0.12 mmol, Yield: 88%); ^1H NMR (400 MHz, CDCl_3) δ 8.67 – 8.18 (m, 1H), 7.52 (ddd, J = 8.4, 7.2, 1.9 Hz, 1H), 7.30 (d, J = 2.0 Hz, 1H), 7.22 (d, J = 2.0 Hz, 1H), 6.86 (d, J = 8.4 Hz, 1H), 6.82 (dd, J = 7.2, 5.0 Hz, 1H), 4.30 (t, J = 8.3 Hz, 2H), 3.07 (t, J = 8.3 Hz, 2H), 0.98 (s, 9H); ^{13}C NMR (101 MHz, CDCl_3) δ


155.74, 147.60, 145.12, 136.48, 135.97, 133.62, 127.24, 116.14, 113.43, 112.87, 110.95, 108.31, 76.01, 53.87, 30.37×3 , 28.60, 27.96; HRMS (ESI): m/z calculated for $[C_{19}H_{20}BrN_2]^+$ [M + H]⁺: 355.0810, Found: 355.0811; FTIR (NaCl): ν 2968, 2899, 2222, 1593, 1469, 1359, 1321, 1213, 1153, 910, 862 cm⁻¹

7-(phenylethynyl)-1-(pyridin-2-yl)indoline (6s)



Following the general reaction procedure E, **6s** was obtained as a yellow solid (27.8 mg, 0.09 mmol, Yield: 67%); m.p. = 97–99 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.42 – 8.30 (m, 1H), 7.46 (ddd, *J* = 8.4, 7.8, 1.9 Hz, 1H), 7.31 (d, *J* = 7.8 Hz, 1H), 7.24 – 7.15 (m, 4H), 7.00 (d, *J* = 8.4 Hz, 1H), 6.98 – 6.92 (m, 2H), 6.89 (t, *J* = 7.6 Hz, 1H), 6.86 – 6.78 (m, 1H), 4.36 (t, *J* = 8.3 Hz, 2H), 3.13 (t, *J* = 8.3 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 155.54, 147.57, 145.98, 135.86, 134.48, 131.38, 130.98 × 2, 128.00 × 2, 127.80, 125.00, 123.36, 121.28, 116.08, 113.26, 108.12, 98.33, 87.81, 53.66, 28.67; HRMS (ESI): m/z calculated for $[C_{21}H_{17}N_2]^+$ [M + H]⁺: 297.1392, Found: 297.1395; FTIR (NaCl): ν 3051, 2916, 2848, 2303, 1589, 1467, 1431, 1265, 1153, 1066, 894, 702 cm⁻¹


7-ethynylindoline (6a')



Following the reported method^[3,4], **6a'** was obtained as a colorless oil (13.3 mg, 0.09 mmol, Yield: 62%); ¹H NMR (400 MHz, CDCl₃) δ 7.17 – 7.03 (m, 2H), 6.60 (t, *J* = 7.5 Hz, 1H), 4.21 (s, NH), 3.63 (t, *J* = 8.4 Hz, 2H), 3.25 (s, 1H), 3.07 (t, *J* = 8.4 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 154.32, 130.03, 128.85, 125.16, 117.88, 101.81, 80.84, 80.66, 46.98, 29.83; HRMS (ESI): m/z calculated for $[C_{10}H_{10}N]^+$ [M + H]⁺: 144.0813, Found: 144.0815; FTIR (NaCl): ν 3390, 3288, 2916, 2848, 2096, 1595, 1469, 1334, 1055, 1028 cm⁻¹




c1 was obtained as a red solid. ¹H NMR (400 MHz, CDCl₃) δ 8.77 (dd, *J* = 5.8, 1.8 Hz, 1H), 7.54 (ddd, *J* = 8.8, 7.3, 1.8 Hz, 1H), 7.37 (d, *J* = 7.3 Hz, 1H), 6.90 (t, *J* = 7.3 Hz, 1H), 6.77 (dd, *J* = 7.3, 1.8 Hz, 1H), 6.74 – 6.65 (m, 1H), 6.54 (d, *J* = 8.8 Hz, 1H), 3.98 (td, *J* = 9.8, 5.8 Hz, 1H), 3.70 (dd, *J* = 18.7, 9.8 Hz, 1H), 3.35 – 3.18 (m, 2H), 1.39 (s, 15H); ¹³C NMR (101 MHz, CDCl₃) δ 154.11, 153.25, 141.54, 140.04, 139.74, 137.62, 137.59, 124.64, 124.60, 118.90, 114.62, 107.87, 95.61 × 2, 95.55 × 2, 48.36, 28.55, 8.82 × 5; HRMS (ESI): m/z calculated for $[C_{23}H_{26}N_2Rh]^+$ [M – Cl]⁺: 433.1151, Found: 433.1146; FTIR (NaCl): ν 3583, 3053, 2914, 1593, 1469, 1431, 1265, 894, 738 cm⁻¹





3a

2154-20-1, 1H, AV 400 MHz, 20140801




AV400 MHz, YXP-1086-2a, 11 Feb 2014, 13C







2106-20-1, 1H NMR, CDCl₃, BBFO-01, Jul 14




2106-20-1, 1H NMR, CDCl₃, BBFO-01, Jul 14







2106-20-2, 1H NMR, CDCl₃, BBFO-01, Jul 14






2106-20-2, 1H NMR, CDCl₃, BBFO-01, Jul 14






1116-20-2, BBFC01







1122-20-2, BBFC01




1122-20-2, BBFC01







11088-20-1, BBFC01, ¹H-NMR,




11088-20-1, BBFC01, ¹H-NMR,







1106-20-1, BBFC01, ¹H-NMR,




1106-20-1, BBFC01, ¹H-NMR,







1128-20-1, BBFC01




1128-20-1, BBFC01







1106-20-22, BBFC01, ^1H -NMR,




1106-20-2, BBFC01, ^1H -NMR,







1116-20-1, BBFC01




1116-20-1, BBFC01







1108-20-3, BBFC1, ^1H -NMR,




1108-20-3, BBFC1, ^1H -NMR,







3l

1108--20-2, AV500




1108-20-2, BBFC1, 1H-NMR,







2228-10-1A, BBF01, Oct 14




2228-10-1a, 1H CDCl₃, oct2014, bbfc02










2226-20-2, 1H, AV 400MHz, 20141001



2226-20-2, 1H, AV 400MHz, 20141001










3p

1132-10-1, BBFC01




1132-10-1, BBFC01







1132-10-2, BBFC01




1132-10-2, BBFC01







3r

1162-10, BBFO1






1162-10, BBFO1






1158-10, BBFO1







2134-10, 1H NMR, CDCl₃, BBFO-01, Jul 14




2134-10, 1H NMR, CDCl₃, BBFO-01, Jul 14







3u

1162-20-1, BBFC01




1162-20-1, BBFC1







2104-20aa, ^1H NMR, CDCl₃, BBFO-01, Jul 14




20104-20aa, ^1H NMR, CDCl₃, AV400, 20140701







2114-20, 1H NMR, CDCl₃, BBFO-01, Jul 14




2114-20, 1H NMR, CDCl₃, BBFO-01, Jul 14




2114-20, ¹H NMR, CDCl₃, BBFO-01, Jul 14







1150-10-1, BBFC01




1150-10-1, BBFC01







1144-20-1q, BBFO1




1144-20-1q, BBFO1







1144-20-2q, BBFO1




1144-20-2q, BBFO1







1144-10-2a, BBFO1




1144-10-2a, BBFO1







5a

1270-10b, BBFO1, MAY 14




1270-10b, BBFO1, MAY 14







5b

2070-10, 1H NMR, CDCl₃, BBFO-01, Jul 14




2070-20, 13C NMR, CDCl₃, AV400, 20140703








3p'


1180-0 CDCl₃ BBFO1 400 Apr




1180-0 CDCl₃ BBFO1 400 Apr









1236-20-1b CDCl₃ BBFO1 400 Apr




1236-20-1a CDCl₃ BBFO1 400 Apr







1224-10, BBFO1, MAY 14




1224-10, BBFO1, MAY 14










1210-10 CDCl₃ BBFO1 400 Apr




1210-10 CDCl₃ BBFO1 400 Apr









2122-10-1, BBOF1, Aug 14




2122-10-1, BBOF1, Aug 14







1252-10, BBFO1, MAY 14




1252-10, BBFO1, MAY 14







2122-10-2, BBOF1, Aug 14




2122-10-2, BBOF1, Aug 14




2122-10-2, BB0F1, Aug 14







1238-20b CDCl₃ BBFO1 400 Apr




1238-20b CDCl₃ BBFO1 400 Apr







tes, 1H NMR, CDCl₃, BBFO-01, Jul 14




tes, 1H NMR, CDCl₃, BBFO-01, Jul 14







tbs-2, 1H NMR, CDCl₃, BBFO-01, Jul 14




t1s, 1H NMR, CDCl₃, BBFO-01, Jul 14







1270-20, 1H, CDCl₃, 400MHz, AV400




1270-20, 1H, CDCl₃, 400MHz, AV400









2040-10a, BBFO 1




2040-10a, BBFO 1









2098-10a, 1H NMR, CDCl₃, BBFO-01, Jul 14




2098-10a, 1H NMR, CDCl₃, BBFO-01, Jul 14









1268-30,


AV500, May 14




1268-30, AV500, May 14, 13C











2084-30, 1H NMR, CDCl₃, BBFO-01, Jul 14




2084-30, 1H NMR, CDCl₃, BBFO-01, Jul 14









2144-10, BBOF1, Aug 14




2144-10, BBOF1, Aug 14






823, 1H, AV 400 MHz, 20140801





823, 1H, AV 400 MHz, 20140801



X-ray Data



X-Ray Structure for 3a

Cambridge Crystallographic Data Centre Deposition Number: 1029305




X-Ray Structure for 6b

Cambridge Crystallographic Data Centre Deposition Number: 1029306



X-Ray Structure for c1

Cambridge Crystallographic Data Centre Deposition Number: 1029307



Reference:

- [1] S. Wagaw, S. L. Buchwald, *J. Org. Chem.*, **1996**, *61*, 7240.
- [2] J. P. Brand, J. Waser, *Angew. Chem. Int. Ed.*, **2010**, *49*, 7304.
- [3] V. Smout, A. Peschiulli, S. Verbeeck, E. A. Mitchell, W. Herrebout, P. Bultinck, C. M. L. V. Velde, D. Berthelot, L. Meerpoel, B. U. W. Maes, *J. Org. Chem.* **2013**, *78*, 9803.
- [4] K. D. Collins, F. Lied, F. Glorius, *Chem. Commun.* **2014**, *50*, 4459.